UB Paderborn / Katalog / Suche / in CDI

1 – 18 von 18

Sortiert nach

Dynamic changes in immune cell populations by AXL kinase targeting diminish liver inflammation and fibrosis in experimental MASH

Frontiers in immunology, 2024-05, Vol.15, p.1400553

2024

Link zum Volltext

Verfügbarkeit prüfen

AXL targeting by a specific small molecule or monoclonal antibody inhibits renal cell carcinoma progression in an orthotopic mice model

Physiological reports, 2021-12, Vol.9 (23), p.e15140-n/a

2021

Link zum Volltext

Verfügbarkeit prüfen

S100A14 inhibits proliferation of oral carcinoma derived cells through G1-arrest

Oral oncology, 2012-03, Vol.48 (3), p.219-225

2012

Link zum Volltext

Verfügbarkeit prüfen

598 Bemcentinib + pembrolizumab show promising efficacy in metastatic NSCLC harbouring mutations associated with poor prognosis: exploratory sub-analysis from the BGBC008 trial (NCT03184571)

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A680-A681

2023

Link zum Volltext

Verfügbarkeit prüfen

MO434: Bemcentinib Targets Macrophage and Mesangial Cells in Renal Fibrosis

Nephrology, dialysis, transplantation, 2022-05, Vol.37 (Supplement_3)

2022

Link zum Volltext

Verfügbarkeit prüfen

The AXL inhibitor bemcentinib reduces inflammation and fibrosis by inducing a dynamic change in macrophages and CD8+T cells subsets during experimental NASH

Journal of hepatology, 2022-07, Vol.77, p.S672

2022

Link zum Volltext

Verfügbarkeit prüfen

MO074TILVESTAMAB, A FUNCTION-BLOCKING MONOCLONAL ANTIBODY INHIBITOR OF AXL RTK SIGNALLING, LIMITS THE ONSET OF RENAL FIBROTIC CHANGES IN HUMAN KIDNEYS EX VIVO

Nephrology, dialysis, transplantation, 2021-05, Vol.36 (Supplement_1)

2021

Link zum Volltext

Verfügbarkeit prüfen

Abstract 3774: BGB324, a selective small-molecule inhibitor of receptor tyrosine kinase AXL, targets tumor immune suppression and enhances immune checkpoint inhibitor efficacy

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.3774-3774

2018

Link zum Volltext

Verfügbarkeit prüfen

Abstract 626: BGB324, a selective small molecule inhibitor of receptor tyrosine kinase AXL, abrogates tumor intrinsic and microenvironmental immune suppression and enhances immune checkpoint inhibitor efficacy in lung and mammary adenocarcinoma models

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.626-626

2017

Link zum Volltext

Verfügbarkeit prüfen

Abstract 3245: AXL as a therapeutic target in STK11 mutant NSCLC

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (7_Supplement), p.3245-3245

2023

Link zum Volltext

Verfügbarkeit prüfen

Abstract 566: BGB324, a selective small molecule inhibitor of the receptor tyrosine kinase AXL, enhances immune checkpoint inhibitor efficacy

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.566-566

2016

Link zum Volltext

Verfügbarkeit prüfen

Flow cytometry-based functional selection of RNA interference triggers for efficient epi-allelic analysis of therapeutic targets

BMC biotechnology, 2014-06, Vol.14 (1), p.57-57, Article 57

2014

Link zum Volltext

Verfügbarkeit prüfen

Abstract 1747: BGB324, a selective small molecule Axl kinase inhibitor to overcome EMT-associated drug resistance in carcinomas: Therapeutic rationale and early clinical studies

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.1747-1747

2014

Link zum Volltext

Verfügbarkeit prüfen

Abstract B30: Selective small molecule AXL inhibitor BGB324 overcomes acquired drug resistance in non-small cell lung carcinoma models

Clinical cancer research, 2014-01, Vol.20 (2_Supplement), p.B30-B30

2014

Link zum Volltext

Verfügbarkeit prüfen

Abstract B014: BGB324, a selective small molecule inhibitor of the receptor tyrosine kinase AXL, enhances immune checkpoint inhibitor efficacy

Cancer immunology research, 2016-01, Vol.4 (1_Supplement), p.B014-B014

2016

Link zum Volltext

Verfügbarkeit prüfen

Abstract B027: BGB324, a selective small molecule inhibitor of AXL receptor tyrosine kinase, enhances immune checkpoint inhibitor efficacy

Cancer immunology research, 2016-11, Vol.4 (11_Supplement), p.B027-B027

2016

Link zum Volltext

Verfügbarkeit prüfen

Drug target discovery using retroviruses

Expert opinion on drug discovery, 2007-10, Vol.2 (10), p.1285-1300

2007

Link zum Volltext

Verfügbarkeit prüfen

Expanding the spectrum of genetic elements transferable by retroviral vectors

DNA and cell biology, 2007-11, Vol.26 (11), p.773

2007

Link zum Volltext

Verfügbarkeit prüfen

1 – 18 von 18

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(18)
Mit Volltextzugriff
(17)

Publikationsform

Artikel
(18)

Sprache

Englisch
(18)
Japanisch
(1)

Erscheinungsjahr

n.n

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Dynamic changes in immune cell populations by AXL kinase targeting diminish liver inflammation and fibrosis in experimental MASH

AXL targeting by a specific small molecule or monoclonal antibody inhibits renal cell carcinoma progression in an orthotopic mice model

S100A14 inhibits proliferation of oral carcinoma derived cells through G1-arrest

598 Bemcentinib + pembrolizumab show promising efficacy in metastatic NSCLC harbouring mutations associated with poor prognosis: exploratory sub-analysis from the BGBC008 trial (NCT03184571)

MO434: Bemcentinib Targets Macrophage and Mesangial Cells in Renal Fibrosis

The AXL inhibitor bemcentinib reduces inflammation and fibrosis by inducing a dynamic change in macrophages and CD8+T cells subsets during experimental NASH

MO074TILVESTAMAB, A FUNCTION-BLOCKING MONOCLONAL ANTIBODY INHIBITOR OF AXL RTK SIGNALLING, LIMITS THE ONSET OF RENAL FIBROTIC CHANGES IN HUMAN KIDNEYS EX VIVO

Abstract 3774: BGB324, a selective small-molecule inhibitor of receptor tyrosine kinase AXL, targets tumor immune suppression and enhances immune checkpoint inhibitor efficacy

Abstract 626: BGB324, a selective small molecule inhibitor of receptor tyrosine kinase AXL, abrogates tumor intrinsic and microenvironmental immune suppression and enhances immune checkpoint inhibitor efficacy in lung and mammary adenocarcinoma models

Abstract 3245: AXL as a therapeutic target in STK11 mutant NSCLC

Abstract 566: BGB324, a selective small molecule inhibitor of the receptor tyrosine kinase AXL, enhances immune checkpoint inhibitor efficacy

Flow cytometry-based functional selection of RNA interference triggers for efficient epi-allelic analysis of therapeutic targets

Abstract 1747: BGB324, a selective small molecule Axl kinase inhibitor to overcome EMT-associated drug resistance in carcinomas: Therapeutic rationale and early clinical studies

Abstract B30: Selective small molecule AXL inhibitor BGB324 overcomes acquired drug resistance in non-small cell lung carcinoma models

Abstract B014: BGB324, a selective small molecule inhibitor of the receptor tyrosine kinase AXL, enhances immune checkpoint inhibitor efficacy

Abstract B027: BGB324, a selective small molecule inhibitor of AXL receptor tyrosine kinase, enhances immune checkpoint inhibitor efficacy

Drug target discovery using retroviruses

Expanding the spectrum of genetic elements transferable by retroviral vectors

Suchergebnisse filtern